Vera Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

Vera Therapeutics, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders voted on three key proposals. First, three Class II Directors—Michael M. Morrisey, Ph.D., Patrick G. Enright, and James R. Meyers—were elected to serve until the 2029 Annual Meeting. Second, the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Finally, stockholders approved, on an advisory basis, the compensation of the company's named executive officers. As of the record date, March 24, 2026, there were 71,713,905 shares of Class A common stock outstanding and entitled to vote. The filing confirms the continuation of current board leadership and auditor oversight without any reported changes to the company's strategic direction or clinical operations.